Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AMARIN CORP PLC\UK Logo
Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.
United States of America AMRN
AMGEN INC Logo
Biotech pioneer developing innovative human therapeutics for the world's toughest diseases.
United States of America AMGN
Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.
South Korea 092040
AMICUS THERAPEUTICS, INC. Logo
Develops advanced therapies for rare lysosomal storage disorders.
United States of America FOLD
AMINOLOGICS CO.,LTD. Logo
Manufactures high-purity chiral amino acids & APIs for pharma, chemical, and food industries.
South Korea 074430
Amneal Pharmaceuticals, Inc. Logo
Develops & commercializes essential medicines: generics, injectables & specialty drugs.
United States of America AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops and manufactures complex injectable, intranasal, and inhalation pharmaceutical products.
United States of America AMPH
Amylyx Pharmaceuticals, Inc. Logo
Developing novel therapies for neurodegenerative diseases like ALS and Wolfram syndrome.
United States of America AMLX
AN2 Therapeutics, Inc. Logo
Developing novel small molecule drugs for infectious diseases and oncology using boron chemistry.
United States of America ANTX
Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.
United Kingdom ANAN

Talk to a Data Expert

Have a question? We'll get back to you promptly.